2503 ORAL Erlotinib (E) versus temozolomide (TMZ) or BCNU in recurrent glioblastoma multiforme (GBM): results from a randomized phase II trial (EORTC 26034)
Martin J. van den Bent(Erasmus MC Cancer Institute), T. Gorlia(Roche (Switzerland)), Mathilde C.M. Kouwenhoven, R. Rampling(Cancer Research UK), J. Kros, Barbara Klughammer(Roche (Switzerland)), Alain Carpentier(Hôpital Saint-Louis), Paul M. Clément(Universitair Ziekenhuis Leuven), Denis Lacombe(European Organisation for Research and Treatment of Cancer), A.A. Brandes(Ospedale Bellaria)
Cited by 5
Related Papers
EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood
|Nature Reviews Clinical Oncology|2020|1.9k
Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions
|Neuro-Oncology|2020|1.1k
Response assessment criteria for brain metastases: proposal from the RANO group
|The Lancet Oncology|2015|1.1k
Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial
|The Lancet|2005|1k
Lomustine and Bevacizumab in Progressive Glioblastoma
|New England Journal of Medicine|2017|994